The Value of Tumor Treating Fields in Glioblastoma
- Author:
Chaochao ZHANG
1
;
Jianyang DU
;
Weidong XU
;
Haiyan HUANG
;
Li GAO
Author Information
- Publication Type:Review Article
- From:Journal of Korean Neurosurgical Society 2020;63(6):681-688
- CountryRepublic of Korea
- Language:English
- Abstract: Glioblastoma (GBM) is one of the most common tumors of the central nervous system, which is the most lethal brain cancer. GBM treatment is based primarily on surgical resection, combined with radiotherapy and chemotherapy. Despite the positive treatment, progression free survival and overall survival were not significantly prolonged because GBM almost always recurs. We are always looking forward to some new and effective treatments. In recent years, a novel treatment method called tumor treating fields (TTFields) for cancer treatment has been proposed. TTFields devices were approved by the Food and Drug Administration (FDA) for adjuvant treatment of recurrent and newly diagnosed GBMs in 2011 and 2015, respectively. This became the first breakthrough treatment for GBM in the past 10 years after the FDA approved bevacizumab for patients with relapsed GBM in 2009. This paper summarized the research results of TTFields in recent years and elaborated the mechanism of action of TTFields on GBM, including cell and animal experimental research, clinical application and social benefits.
